Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

34 questions · 34 findings · 12 reviews · Musculoskeletal

No studies found 8 · 23.5%GRADE not reported 4 · 11.8%Very low 8 · 23.5%Low 10 · 29.4%Moderate 3 · 8.8%High 1 · 2.9%

Combination of manual therapy and exercise following joint distension vs sham ultrasound following joint distension

Adverse events · patients with adhesive capsulitis (frozen shoulder)

Combination of manual therapy and exercise following joint distension leads to lower adverse events compared with sham ultrasound following joint distension (high certainty).

1 finding from 1 review

Low‐dose colchicine vs placebo

Total adverse events · acute gout

Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).

1 finding from 1 review

Autologous blood or PRP vs placebo at 3 months' follow‐up

Adverse events (pain and swelling at injection site and limitation of elbow movement following injection) · lateral elbow pain

Autologous blood or PRP showed no clear difference in adverse events (pain and swelling at injection site and limitation… compared with placebo at 3 months' follow‐up (low certainty).

1 finding from 1 review

Low‐dose colchicine vs NSAIDs

Number of participants reporting an adverse event · acute gout

Low‐dose colchicine showed no clear difference in total number of participants reporting adverse events compared with NSAIDs (low certainty).

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Anti‐TNF dose reduction vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF discontinuation vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).

1 finding from 1 review

Anti‐TNF dose reduction vs anti‐TNF continuation

Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Withdrawals due to adverse events not measured · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

The review found no eligible studies for this question.

1 finding from 1 review